Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE

[1]  A. Torbicki,et al.  Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. , 2020, The New England journal of medicine.

[2]  Jin Yang,et al.  Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants , 2020, Medicine.

[3]  C. Flowers,et al.  Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Combescure,et al.  Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis , 2019, PloS one.

[5]  C. Loprinzi,et al.  Apixaban, Dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial , 2018, Blood.

[6]  A. Khorana,et al.  Role of direct oral anticoagulants in the treatment of cancer‐associated venous thromboembolism: guidance from the SSC of the ISTH , 2018, Journal of thrombosis and haemostasis : JTH.

[7]  A. Marshall,et al.  Anticoagulation therapy in SELECTeD cancer patients at risk of recurrence of venous thromboembolism : results of the 'select-d' Pilot Trial , 2018 .

[8]  G. Raskob,et al.  Edoxaban for the Treatment of Cancer‐Associated Venous Thromboembolism , 2017, The New England journal of medicine.

[9]  A. Marshall,et al.  Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D™ Pilot Trial , 2017 .

[10]  Chau-Chung Wu,et al.  Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review , 2017, Thrombosis and Haemostasis.

[11]  A. Tjønneland,et al.  The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort , 2017, Journal of thrombosis and haemostasis : JTH.

[12]  J. Douketis,et al.  International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. , 2016, The Lancet. Oncology.

[13]  W. Ageno,et al.  Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE) , 2016, Thrombosis and Haemostasis.

[14]  A. Khorana,et al.  Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed? , 2016, Thrombosis research.

[15]  G. Raskob,et al.  Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. , 2016, Cancer research.

[16]  S. Eichinger.  Cancer associated thrombosis: risk factors and outcomes. , 2016, Thrombosis research.

[17]  W. Ageno,et al.  Management of recurrent venous thromboembolism in cancer patients. , 2016, Thrombosis research.

[18]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[19]  Gary H Lyman,et al.  Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Braekkan,et al.  Epidemiology of cancer-associated venous thrombosis. , 2013, Blood.

[21]  Stephen T Kee,et al.  Diagnosis and management of upper extremity deep-vein thrombosis in adults , 2012, Thrombosis and Haemostasis.

[22]  S. Kahn,et al.  Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting , 2012, Thrombosis and Haemostasis.

[23]  R. Zierler,et al.  The Risk Factors and Clinical Outcomes of Upper Extremity Deep Vein Thrombosis , 2012, Vascular and endovascular surgery.

[24]  M. Mandalà,et al.  Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  A. Khorana.  Venous thromboembolism and prognosis in cancer. , 2010, Thrombosis research.

[26]  M. Mandalà,et al.  Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[28]  Gary H Lyman,et al.  Development and validation of a predictive model for chemotherapy-associated thrombosis. , 2008, Blood.

[29]  P. Stein,et al.  Incidence of venous thromboembolism in patients hospitalized with cancer. , 2006, The American journal of medicine.

[30]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[31]  S. Goldhaber,et al.  Upper-Extremity Deep Vein Thrombosis: A Prospective Registry of 592 Patients , 2004, Circulation.

[32]  R. Bick.  Cancer-associated thrombosis. , 2003, The New England journal of medicine.

[33]  B. Davis,et al.  I, RATIONALE AND DESIGN , 1991 .

[34]  北村 聖.  "The New England Journal of Medicine". , 1962, British medical journal.